Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 87 | UKINETS2022 | Next issue

UKI NETS 20th National Conference


Oral Communications

ea0087oc1 | Oral Communications | UKINETS2022

Urine 5-HIAA levels and quality-of-life in neuroendocrine neoplasia. Is there an association?

Chaudhry Rayhan , White Benjamin , Kandiah Chandrakumaran , Vincent Royce , Srirajaskanthan Rajaventhan , Clement Dominique , Ramage John

Introduction: Patients with neuroendocrine neoplasia (NEN) may experience psychological distress related to secretory effects of the tumour. 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite of serotonin, the most important secretory product in carcinoid syndrome. This study aims to determine if urine 5-HIAA levels correlate with health-related quality of life (HRQoL) in patients with NEN.Methods: A retrospective single-centre cohort study was conducte...

ea0087oc2 | Oral Communications | UKINETS2022

Glucagonomas: diagnostic features and outcomes of first line treatment in a series of 18 patients

Porto Juliana , Branton Alexander , Heseth Richard , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos

Introduction: Glucagonomas are rare functional pancreatic neuroendocrine tumours (p NETs), with an annual occurrence of 0.01 to 0.1 new cases per 100,000. Objective: We focused on presenting symptoms, primary’s size and location, presence of metastases, biomarkers at diagnosis, histology, response to first line treatment (clinical and biochemical), disease fee survival (DFS) and PFS (progression free survival). Methods: Eighteen pa...

ea0087oc3 | Oral Communications | UKINETS2022

Outcomes in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours receiving PRRT early versus later

Robinson Matthew D , Chander Amarjot , Westwood Tom , Manoharan Prakash , Mansoor Was , Lamarca Angela , A Hubner Richard , W Valle Juan , G McNamara Mairead

Background: Neuroendocrine tumours (NETs) are rare malignancies; over 60% of primary lesions arise in the gastrointestinal tract and pancreas. Despite several practice-changing clinical trials, uncertainty persists around the most efficacious treatment sequence in patients with advanced well-differentiated gastroenteropancreatic (GEP) NETs, particularly in relation to peptide receptor radionuclide therapy (PRRT). This study aimed to investigate the progression-free survival (P...